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Objective: Differences in treatment patterns, health care resource utilization, and costs between 
patients with castration-resistant prostate cancer (CRPC) treated by oncologists and those treated 
by urologists were examined.
Methods: Patients aged $40 with CRPC were identified using claims from a large US   managed 
health care plan between July 2001 and December 2007. A 6-month baseline period was used to 
assess patient characteristics. Patients with visits to an urologist, without visits to an oncologist, 
were assigned to the urology cohort, and patients with visits to an oncologist, with or without 
visits to an urologist, were assigned to the oncology cohort. Treatment patterns, health care 
resource utilization, and costs during a variable follow-up period were compared between 
cohorts using descriptive statistics and Lin’s regression.
Results: The urology cohort had fewer comorbid illnesses (P , 0.001) and patients were less 
likely to have other cancers during baseline (P , 0.001) or to die during follow-up (P = 0.004) 
compared with the oncology cohort. The oncology cohort patients were significantly more likely 
to have a claim for hormones (74.5% vs 61.1%; P , 0.001), chemotherapy (46.9% vs 10.2%, 
P , 0.001), and radiation (22.3% vs 3.7%, P , 0.0001) over follow-up. Mean unadjusted 
health care costs were higher in the oncology vs the urology cohort (US$31,896 vs US$15,318, 
respectively; P , 0.001). At 6 years follow-up, cumulative adjusted CRPC-specific costs were 
significantly higher among patients treated by oncologists with chemotherapy than among 
patients treated by urologists.
Conclusion: CRPC patients treated by oncologists had greater use of hormones,   chemotherapy, 
and radiation; higher percentages of patients with inpatient stays, emergency room, and 
ambulatory visits; and higher health care costs, than patients treated by urologists.
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Introduction
Prostate cancer is the most common malignancy diagnosed among men in the US,1 
with an incidence rate of 156.9 per 100,000 men.2 It has been reported that one in 
six American men will develop prostate cancer during the course of his lifetime.3,4 
Incidence rates vary considerably by country; by far the highest rates are seen in the 
US and Canada.5 In 2010, about 217,730 new cases of prostate cancer will have been 
diagnosed in the US, and roughly 32,050 men will have succumbed to the disease.2
Most patients with prostate cancer die from other causes and not from the disease 
itself,6,7 especially in cases where the cancer is slow-growing (as is the case in two-thirds Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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of patients), asymptomatic, or nonmetastatic.8,9 Survival rates 
are high for localized and regional prostate cancer (100%), 
but drop dramatically to 31% for metastatic disease.9
Castration-resistant prostate cancer (CRPC) is defined 
by disease progression despite castrate levels of testosterone 
and may present as one or any combination of a continuous 
rise in serum levels of prostate-specific antigen, progression 
of pre-existing disease, or appearance of new metastases. 
Patients with CRPC have a poorer prognosis than patients 
with earlier-stage prostate cancer and frequently have meta-
static disease, especially to bone. Men with CRPC who are 
resistant to docetaxel-based or other systemic therapy invari-
ably progress and die from the disease.10 According to the 
National Cancer Institute, metastatic prostate cancer (HRPC)
was associated with a relative 5-year survival rate of 30.2% 
during the period 2003–2007, in contrast to 100% 5-year 
survival rates among patients with localized or regional 
prostate cancer.11 In the IMPACT study, a Phase III study 
of patients with advanced prostate cancer, median survival 
time for patients with metastatic CRPC was 21.4 months, 
with slightly improved survival (25.9 months) among men 
receiving the Provenge® (sipuleucel-T, Dendreon, Seattle, 
WA) vaccine.12
Treatment options for CRPC include secondary hormonal 
manipulations, palliative radiotherapy, and radiotherapeutics 
(eg, strontium-89), steroids, bisphosphonates to preserve 
bone health and to prevent skeletal complications in patients 
with bone metastases, and the chemotherapeutic agents 
docetaxel, estramustine, mitoxantrone, and cabazitaxel.13–17 
Although treatments for advanced prostate cancer have 
largely focused on palliative care, more men are likely to 
be offered chemotherapy for advanced-stage disease than 
in the past because of the survival benefit reported with 
docetaxel-based chemotherapy across patient subgroups.18 
Based on the significant survival benefit conferred by doc-
etaxel in patients with metastatic hormone-resistant prostate 
cancer (HRPC) and CRPC16,19 and its demonstrated effec-
tiveness across a wide range of ages,20,21 docetaxel-based 
chemotherapy has become the current standard of care for 
patients with CRPC. However, it is not considered curative 
and, in some clinical trials, has been shown to increase the 
median survival by only 2.4 months.16 In June 2010, the 
FDA approved Jevtana® (cabazitaxel, sanofi-aventis, Bridge-
water, NJ) injection in combination with prednisone for 
the treatment of patients with metastatic HRPC previously 
treated with a docetaxel-containing treatment regimen. In 
addition, Provenge, an autologous cellular immunotherapy, 
was approved by the FDA in April 2010 for treatment of   
asymptomatic or minimally symptomatic metastatic CRPC 
after a survival advantage was demonstrated.
The care of men with advanced prostate cancer is gener-
ally under the direction of urologists, although multispecialty 
groups of urologists and radiation oncologists working in 
tandem have become increasingly common.22 A study in 
which 3000 urologists were surveyed showed that only 4% of 
the 654 urologists who responded were trained to administer 
chemotherapy to the 64% of their patients who had prostate 
cancer, and roughly 30% of their patients were referred to 
an oncologist. However, only 19% of the patients under the 
care of these urologists had HRPC and 21% had metastatic 
disease.23
Investigators have called for an integrated multidis-
ciplinary approach to treatment involving urologists, 
oncologists, radiation oncologists, and pathologists to 
ensure optimal patient care.24–27 Patients benefit from such 
an approach because of the spectrum of expertise encom-
passed by these various specialists, with the potential for 
more comprehensive health care if treatment is sought from 
more than one type of specialist. Previous studies have 
compared prostate cancer treatment approaches of urolo-
gists to those of oncologists,23,28–31 but they have largely been 
confined to the study of patients with early-stage disease, 
leaving a gap in understanding of the comparative treatment 
approaches between these two types of specialists for late-
stage disease.
Because of the prolonged survival and intense treatment 
needs CRPC patients can have after diagnosis, there is an 
increased likelihood that their use of health care resources 
and costs could represent a significant economic burden.13,32 
In general, prostate cancer is associated with expenditures 
of roughly US$7 billion annually33,34 and was reported to 
be the third most costly cancer among elderly Medicare 
patients diagnosed in 2004.35 There is a greater preponder-
ance of literature on the economic burden of prostate cancer 
in a general population of US patients rather than the CRPC 
population.
The present study was designed to assess treatment pat-
terns, health care resource utilization, and costs in a popula-
tion of patients identified with CRPC, stratified by type of 
specialist (oncologist or urologist) visited by the patient.
Methods
study design
This was a retrospective claims data analysis using medical 
and pharmacy data, enrollment information, and labora-
tory results obtained from a large US managed care claims Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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database. Data from July 1, 2001 through December 31, 2008 
(the study period) were used. As of 2007, data for approxi-
mately 35.4 million individuals receiving both medical and 
pharmacy benefits were available.
Patient identification
Patients were identified from a previously conducted burden-
of-illness study.20 To summarize patient selection for that 
study, initial inclusion criteria required commercially insured 
and Medicare Advantage enrollees to be at least 40 years of 
age as of the year of the index date. Loosely defined, the index 
date was the time when patients’ cancer became castration 
resistant. Moreover, patients had to have at least one medical 
claim with an International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) diagnosis code 
for prostate cancer (185 [malignant neoplasm of the prostate] 
or 233.4 [prostate cancer]), to be continuously enrolled in the 
health plan for 180 days prior to the index date (pre-index 
period) and for a minimum of 30 days following the index 
date (post-index period), and to have evidence of surgical or 
medical castration during the study period. A more detailed 
description of the study population selection was published 
previously.20
Included patients were required to have had at least three 
laboratory results for the prostate-specific antigen (PSA) test 
between the castration date and December 1, 2007; however, 
hormone-treated patients with fewer than three PSA labo-
ratory values were considered for study inclusion if they 
received at least one of the following services, which must 
have occurred at least 2 days following surgical castration or 
14 days following the initiation of medical castration: a) at 
least one pharmacy claim or medical claim for docetaxel, 
b) a bone X-ray or bone scan, c) at least one PSA test, d) at 
least one office visit with an oncologist for prostate cancer, 
or e) at least one office visit.
Patients defined as having known CRPC or as not having 
CRPC based on PSA results were selected for inclusion in a 
model of CRPC status in order to determine which patients 
initially assigned an unknown CRPC status likely had CRPC. 
Logistic regression was used to model known CRPC status 
as a function of age, baseline comorbidity, baseline CRPC-
specific costs, length of post-index enrollment, time from 
castration to index date, docetaxel use, evidence of bone 
X-ray or bone scan, number of PSA tests identified in the 
medical claims, and evidence of oncology or urology office 
visits. A detailed explanation of this modeling approach and 
its application to the patient sample is provided in the previ-
ously published article by Alemayehu et al.20
Cohort assignment by physician specialty
Assignment to either the oncologist (oncology) cohort or 
the urologist (urology) cohort was based on the specialty of 
the physician visited by the patient during the study period. 
Patients with at least one visit to an oncologist (at any non-
laboratory site) during either the baseline or follow-up period, 
with or without visits to an urologist, were assigned to the 
oncology cohort, and patients with at least one visit to an 
urologist (at any nonlaboratory site) during either the baseline 
or follow-up period, without a visit to an oncologist, were 
assigned to the urology cohort. The oncology cohort includes 
a high percentage of patients seen by both an urologist and 
an oncologist. Typically, patients who are not deemed by an 
urologist to be candidates for chemotherapy would not be 
referred to an oncologist.
study measures
Patient demographic and clinical characteristics were evalu-
ated at baseline. Index month and year of diagnosis of CRPC, 
patient age, category of age (40–54; 55–64; 65–74; 75+), 
insurance type (commercial or Medicare Advantage), and 
geographic census region in which the patient was enrolled 
in a health plan (Northeast, South, West, or Midwest) were 
determined from enrollment data and medical and pharmacy 
claims. Clinical characteristics included pre-index Charlson 
comorbidity score, pre-index comorbid conditions, evidence 
of death during follow-up based on hospital discharge status, 
and evidence of other cancer based on Agency for Health-
care Research and Quality (AHRQ) Clinical Classification 
disease condition variables created in the original study for 
the pre-index period.
The use of hormone therapy, chemotherapy (see 
Appendix), radiation therapy, and the use of medications 
and other treatments for specific chemotherapy-related and 
cancer-related effects were examined during the baseline and 
follow-up periods using medical and pharmacy claims.
All-cause and CRPC-specific health care utilization 
were identified from medical claims for ambulatory visits, 
emergency department visits, and inpatient admissions 
during the pre- and post-index periods. Ambulatory visits 
included physician office visits and visits to an outpatient   
facility (including outpatient procedures, outpatient services, 
and outpatient laboratory and radiology). Any ambulatory 
or emergency department visit with a primary diagnosis of 
prostate cancer, primary diagnosis or procedure code for sur-
gical or medical castration, primary diagnosis or procedure 
code for PSA tests (CPT codes 84152, 84153, or 84154; 
HCPCS G0103 or G9080; or ICD-9 diagnosis code 790.93), Cancer Management and Research 2011:3
Table 1 Patient demographic and clinical characteristics at baseline
Characteristic Oncology  
cohort  
(n = 1,590) %
Urology  
cohort  
(n = 995) %
P-value
Age group
  40–54 4.59 1.41 ,0.001
  55–64 24.09 15.68
  65–74 31.45 23.82
  75+ 39.87 59.10
insurance type
  Commercial 57.48 49.95 ,0.001
  Medicare advantage 42.52 50.05
health plan region
  Northeast 7.17 13.57 ,0.001
  Midwest 42.01 38.39
  south 42.96 43.52
  West 7.86 4.52
Final treatment  
  cohort counts
61.51 38.49 –
Evidence of death  
  during follow-up
11.45 7.94 0.004
Evidence of other  
  cancers during  
  baseline period
27.36 17.69 ,0.001
Mean [SD] Mean [SD]
Age (continuous) 71.05 [9.72] 75.52 [9.39] ,0.001
Charlson comorbidity 
  score
4.85 [2.44] 3.73 [2.17] ,0.001
Number of AhRQ  
  comorbid conditions
11.14 [6.16] 10.09 [5.98] ,0.001
Abbreviation: AhRQ, Agency for healthcare Research and Quality.
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procedure code for radical prostatectomy (CPT codes 
55810–55815, 55840–55845, 55866, or ICD-9   procedure 
code 60.5), or procedure code for docetaxel infusion (J9170) 
was considered to be CRPC-specific. Any inpatient stay 
with a primary diagnosis of prostate cancer was considered 
CRPC-specific. The monthly incidence of each type of visit 
was calculated, and the count of each type of visit during the 
post-index period was calculated on a per-patient per-month 
(PPPM) basis.
All-cause and CRPC-specific health care costs were 
calculated for overall costs, medical costs (costs from medical 
claims), and pharmacy costs (costs from outpatient pharmacy 
claims for leuprolide, triptorelin, goserelin, histrelin, or 
docetaxel), and were computed as the combined health 
plan- and patient-paid amounts identified from medical 
and pharmacy claims in the post-index period. Pharmacy 
costs were calculated for prescriptions filled at retail or 
mail-order pharmacies. Most chemotherapies were included 
as medical costs since they are administered in an office 
or inpatient setting. All pharmacy claims with a provider 
specialty of oncology or urology were included as CRPC-
specific pharmacy costs. All pre- and post-index costs were 
calculated as costs PPPM, and were adjusted for inflation to 
2008 dollars using the medical component of the Consumer 
Price Index.36
statistical analyses
Descriptive analysis was performed to compare all baseline 
and follow-up measures across the oncology and urology 
cohorts. To assess similarities and differences between the 
cohorts, patient demographics, patient characteristics, and 
utilization were compared using chi-square tests for discrete 
data and t-tests for continuous data. PPPM incidences are 
presented for dichotomous utilization measures. All analyses 
were conducted using SAS (v 9.1; SAS Institute, Inc, Cary, 
NC) and Stata (v 10; StataCorp, College Station, TX).
Multivariate analyses of total and CRPC-specific costs 
adjusted for treatment cohort, age group, baseline radiation 
or hormone therapy use, and Charlson comorbidity score 
and included an interaction term for treatment cohort and 
chemotherapy use. Lin’s weighted regression method37 was 
used to account for censored follow-up time as well as cost 
accumulation at multiple intervals. In this method, the first 
step models the probability of not being censored for all 
subjects. The second step uses a general linear regression 
weighted on the inversed probabilities of not being censored 
to model health care costs in patients who have complete 
follow-up information during the time period.
Results of the models are shown as estimated accumulated 
costs over the entire study period, starting with 1 year of 
costs through 6 years of costs; each cumulative cost figure 
was estimated with a separate model.
Results
study sample
After applying all inclusion and exclusion criteria, a total of 
2585 patients who visited an oncologist or urologist were 
retained for the study, with 61.5% in the oncology cohort 
(n = 1590) and 39.9% in the urology cohort (n = 995). As 
shown in Table 1, mean age was higher in the urology cohort 
than in the oncology cohort (75.5 vs 71.1 years, P , 0.001). 
Patients in the oncology cohort had a higher average   Charlson 
comorbidity score (P , 0.001) and a greater number of 
comorbid illnesses (P , 0.001), and were more likely to 
die during the follow-up period (P = 0.004) or to have other 
cancers during baseline (P , 0.001) compared to patients 
in the urology cohort. A lower percentage of the oncology 
cohort was enrolled in Medicare Advantage plans as com-
pared to the urology cohort.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Figure 1A Use of specific treatments during baseline period.
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Figure1B Use of specific treatments during follow-up period.
Table 2 Use of specific treatments during variable-length follow-
up period
Treatments Oncology  
cohort  
(n = 1590) %
Urology  
cohort  
(n = 995) %
P-value
Hormone treatment 75.4 61.1 ,0.001
Antiandrogens 28.9 18.2 ,0.001
Aromatase inhibitors 0.2 0
Estrogen receptor antagonists 0.3 0
gnRh agonists 6.2 4.7 0.107
LhRh agonists 65.4 54.6 ,0.001
LhRh antagonists 0.1 0
Progestins 15.7 6.6 ,0.001
Estrogens 0.2 0.1
Chemotherapy 46.9 10.2 ,0.001
Alkylating 16.5 3.0 ,0.001
Antimetabolites 4.2 1.7 ,0.001
Docetaxel 38.2 7.0 ,0.001
Other antimicrotubule 8.9 1.1 ,0.001
Topoisomerase-active 12.6 1.2 ,0.001
Antineoplastic antibiotic 0.8 0.2
Biologically directed 2.8 0.8 ,0.001
immune therapies 2.7 0.8 ,0.001
Miscellaneous 0.6 0.3
Treatments for other 
  conditions
83.9 63.0 ,0.001
Anemia 42.8 16.6 ,0.001
Neutropenia 16.0 2.3 ,0.001
Thrombocytopenia 2.2 0.3
Nausea/emesis 63.0 31.9 ,0.001
Pain 67.4 49.9 ,0.001
Abbreviations: gnRh, gonadotropin-releasing hormone; LhRh, luteinizing-hormone-
releasing hormone.
study measures
Use of specific treatments during baseline period
Higher percentages of patients in the oncology cohort used 
hormone treatment, chemotherapy, radiation, or other treat-
ments for specific chemotherapy-related and cancer-related 
effects during the baseline period compared to the   urology 
cohort (Figure 1A). Hormone treatment was the most 
  commonly used treatment for both cohorts, utilized by 78.5% 
of the oncology cohort and 60.6% of the urology cohort 
(P , 0.001). Only 12.9% of the oncology cohort and 3.2% 
of the urology cohort used chemotherapy (P , 0.001).
Use of specific treatments during follow-up period
During follow-up, all treatments evaluated were used by 
significantly higher percentages of patients in the oncology 
cohort compared to the urology cohort (Figure 1B). The 
differences between cohorts were greatest for chemotherapy 
and radiation use, and the smallest difference was seen for 
hormone treatment.
Chemotherapy use increased considerably in the oncology 
cohort from the baseline period (12.9% of patients) to the 
follow-up period (46.9% of patients). A higher percentage of 
patients in the oncology cohort used radiation during follow-up 
than during the baseline period (42.7% vs 22.3%), and the 
same was true for the urology cohort, with 3.7% of patients 
receiving radiation treatment during the baseline period and 
9.8% using radiation during follow-up. Slightly fewer patients 
in the oncology cohort and slightly more patients in the urology 
cohort had hormone treatment during follow-up than during the 
baseline period. In both cohorts, luteinizing-hormone-releasing 
hormone (LHRH) agonists were the most commonly prescribed 
hormone (used by 65.4% of the oncology cohort and 54.6% of 
the urology cohort, P , 0.001) (Table 2). There were high rates 
of treatments for other conditions (eg, anemia, neutropenia, 
pain) in both cohorts, particularly in the oncology cohort.
As shown in Table 3, there were significant differences 
in the incidence rates of hormone treatment, chemotherapy, 
radiation treatment, and other medications between the 
cohorts (P , 0.001 for all comparisons).
In the oncology cohort, first use of chemotherapy 
after diagnosis of CRPC was highest during days 31–182 
of follow-up (36.8% of patients), whereas in the urology Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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cohort, first use of chemotherapy after diagnosis of CRPC 
was highest during the first 30 days of follow-up (7.0% of 
patients). The mean [SD] number of days until first use of 
hormone therapy was 77.1 [149.7] for the oncology cohort 
(range, 0–1980 days) and 87.1 [141.1] for the urology cohort 
(range, 0–1320 days). The mean [SD] number of days until 
first use of chemotherapy was 102.4 [259.0] for the oncology 
cohort (range, 0–2164 days) and 97.8 [223.6] for the urology 
cohort (range, 0–1280 days).
health care resource utilization  
and cost outcomes
Baseline utilization
Total health care utilization was higher for the oncology 
cohort than for the urology cohort with regard to docetaxel 
use during the 6-month baseline period, but differences 
between the cohorts were not significant for inpatient 
stays, emergency room (ER) visits, or ambulatory visits 
(Table 4).
More than 95% of each cohort had an ambulatory visit, 
but less than 30% of each cohort had an ER visit and roughly 
20% of each cohort had an inpatient visit. Mean adjusted 
counts of docetaxel use, inpatient stays, and ambulatory 
visits were significantly higher for the oncology cohort than 
for the urology cohort. Length of inpatient stay did not differ 
significantly between cohorts; oncology patients had a mean 
[SD] length of stay of 8.3 [16.9] days, and urology patients 
had a mean [SD] length of stay of 8.4 [22.3] days. The only 
significant difference between cohorts was in docetaxel use, 
used by 2.6% of the oncology cohort and only 0.6% of the 
urology cohort (P , 0.001). However, there was a significant 
difference between the cohorts with regard to mean adjusted 
count of inpatient stays (mean [SD] 0.8 [1.2] for the oncol-
ogy cohort and mean [SD] 0.6 [1.2] for the urology cohort; 
P , 0.001).
Significant differences in baseline CRPC-specific health 
care utilization were observed between the oncology and 
urology cohorts with regard to docetaxel use, inpatient 
stays, and ambulatory visits, but not with regard to ER visits 
(Table 5).
Follow-up utilization
During the variable-length follow-up period, the oncology 
cohort had significantly higher percentages of patients with 
use of docetaxel, inpatient stays, ER visits, and ambulatory 
visits as compared to the urology cohort (Table 4). In the 
Table 3 Treatment use during variable-length follow-up period – incidence rates*
Treatments Oncology cohort  
(n = 1590)
Urology cohort  
(n = 995)
Oncology vs 
urology cohort
Events Person-time Rate Events Person-time Rate Ratio P-value
hormones 1199 2381 50.36 608 1542 39.42 1.28 ,0.001
Chemotherapy 745 2381 31.29 101 1542 6.55 4.78 ,0.001
Radiation 679 2381 28.52 97 1542 6.29 4.53 ,0.001
Other medications 1334 2381 56.03 627 1542 40.66 1.38 ,0.001
Note: *incidence per 100 person-years.
Table 4 Total health care utilization during baseline and follow-
up periods
Health care 
utilization
Oncology  
cohort  
(n = 1590) %
Urology  
cohort  
(n = 995) %
P-value
Baseline period
Docetaxel use 2.64 0.60 ,0.001
inpatient stay 20.88 20.00 0.590
ER visit 26.86 23.92 0.097
Ambulatory visit 99.81 99.70 0.562
Variable follow-up period
Docetaxel use 38.24 7.04 ,0.001
inpatient stay 60.44 47.64 ,0.001
ER visit 62.96 56.38 ,0.001
Ambulatory visit 99.18 98.19 ,0.001
Abbreviation: ER, emergency room.
Table 5 CRPC-specific health care utilization during baseline and 
follow-up periods
Health care 
utilization
Oncology  
cohort  
(n = 1590) %
Urology  
cohort  
(n = 995) %
P-value
Baseline period
Docetaxel use 2.64 0.60 ,0.001
inpatient stay 9.43 4.12 ,0.001
ER visit 13.77 14.47 0.619
Ambulatory visit 98.93 95.48 ,0.001
Variable follow-up period
Docetaxel use 38.24 7.04 ,0.001
inpatient stay 35.72 12.16 ,0.001
ER visit 33.58 34.87 0.328
Ambulatory visit 97.99 93.07 ,0.001
Abbreviations: CRPC, castration-resistant prostate cancer; ER, emergency room.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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oncology cohort, 63.0% had ER visits over the variable-
length follow-up period (range, 30 days to 6 years), vs 56.4% 
of the urology cohort (P , 0.001). Almost all patients in both 
cohorts had an ambulatory visit during follow-up. More than 
half of the oncology cohort (60.4%) and slightly less than half 
of the urology cohort (47.6%) had an inpatient stay. There 
were significant differences between the cohorts with regard 
to mean per-6-month number of docetaxel claims, ER visits, 
and ambulatory visits.
Significant differences in CRPC-specific health care 
utilization between the oncology and urology cohorts were 
seen during the variable follow-up period with regard to 
docetaxel use, inpatient stays, and ambulatory visits, but not 
ER visits (Table 5).
Baseline costs
Mean total health care costs were US$14,004 for the oncology 
cohort and US$7587 for the urology cohort, P , 0.001. Costs 
for ambulatory visits (office/outpatient visits) accounted for 
the highest mean total costs for both cohorts (Figure 2A).
The lowest cost burden for both of the cohorts was ER-
related costs. There were significant differences between 
the cohorts with regard to mean total, medical, ambulatory, 
and pharmacy costs, but inpatient costs, ER costs, and other 
medical costs were not significantly different between the 
two cohorts.
Mean baseline CRPC-specific total costs were US$8065 
for the oncology cohort and US$3489 for the urology cohort, 
P , 0.001 (Figure 3A).
Costs for ambulatory visits were the greatest expense for 
both cohorts, with a mean of US$6163 and US$2586 for the 
oncology and urology cohorts, respectively; the difference 
between the cohorts was significant (P , 0.001).
The category with the lowest overall cost in both cohorts 
was ER visits. Pharmacy costs were significantly higher for 
the oncology cohort (mean US$703) than for the urology 
cohort (mean US$226), P , 0.001. A significant difference 
between the cohorts was also observed for inpatient costs, 
but these costs were low for both cohorts (mean US$870 
for the oncology cohort and US$365 for the urology cohort, 
P , 0.001).
Follow-up costs
Total health care costs per 6 months were significantly 
higher for the oncology cohort than for the urology cohort 
during the variable-length follow-up period, with a mean 
of US$31,896 per 6 months for the oncology cohort and 
a mean of US$15,318 per 6 months for the urology cohort 
(P , 0.001). Ambulatory visits were the biggest cost driver 
for the oncology cohort (mean US$18,593), and inpatient 
costs represented the highest cost burden for the urology 
cohort (mean US$7635) (Figure 2B).
Mean total CRPC-specific costs per 6 months were 
US$21,518 for the oncology cohort and US$6474 for the 
urology cohort (P , 0.001; Figure 3B).
Significant differences were observed between the 
cohorts with regard to CRPC-specific medical costs, inpatient 
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Figure 3A Baseline CRPC-specific costs (6-month), mean US$.
Abbreviation: CRPC, castration-resistant prostate cancer.
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costs, ambulatory costs, and pharmacy costs. Ambulatory 
visits were the biggest cost driver for both cohorts, with 
mean costs of US$14,058 and US$3682 for the oncology 
and urology cohorts, respectively.
The lowest costs observed in the oncology cohort were 
for ER visits (mean US$238), and the lowest category of 
expense for the urology cohort was pharmacy costs (mean 
US$240).
Multivariate analyses
Results of Lin’s regression analysis confirmed the finding 
that the oncology and urology cohorts differed significantly 
with regard to total costs over the follow-up period, but 
only when patients were using chemotherapy. During the 
first year of follow-up, total adjusted health care costs were 
US$31,792 (urology cohort), US$54,306 (oncology with che-
motherapy, P , 0.001), and US$30,894 (oncology without 
chemotherapy) (Table 6).
Patients in the oncology cohort using chemotherapy 
had an adjusted cumulative total cost of US$168,794 over 
6 years of follow-up; those in the oncology cohort without 
chemotherapy, US$114,180; and patients in the urology 
cohort, $86,706.
In addition to cohort, other factors that were statistically 
significantly associated with total health care costs were 
being in the 55–64 age group, number of PSA tests during 
follow-up (both of which were associated with an increase 
in costs), and baseline use of docetaxel (associated with a 
decrease in costs).
Lin’s regression was also used to assess CRPC-specific 
costs over the follow-up period while accounting for the 
variable length of follow-up in the study population. Again, 
the urology and oncology cohorts differed significantly, but 
the degree of difference varied according to whether patients 
were using chemotherapy. Over 6 years of follow-up, cumu-
lative adjusted CRPC-specific costs were significantly higher 
among patients treated by oncologists with chemotherapy 
than among patients treated by urologists (US$68,286 vs 
US$25,081, P , 0.001). However, statistically significant 
differences in adjusted cumulative CRPC-specific costs 
were not observed between patients treated by oncologists 
without chemotherapy (US$32,927) and patients treated by 
urologists, regardless of follow-up length.
Factors other than cohort that were statistically signifi-
cantly associated with CRPC-specific costs were comorbid-
ity score (associated with a decrease in costs), being in the 
55–64 age group (associated with an increase in costs), and 
number of PSA tests during follow-up (associated with an 
increase in costs).
Discussion
The primary outcomes evaluated in this study indicate 
that disparate treatment patterns are observed between 
oncologists and urologists, regardless of differences in 
patient characteristics and variations in disease severity. 
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Abbreviation: CRPC, castration-resistant prostate cancer.
Table 6 Predicted cumulative total and CRPC-specific health care costs (adjusted)
Cohort Cumulative years
1 1–2 1–3 1–4 1–5 1–6
Adjusted total health care costs (US$)
Urology cohort (ref.) 31,791.58 49,463.35 64,476.63 72,970.69 83,089.42 86,706.26
Oncology with chemotherapy 54,305.81‡ 92,096.22† 123,586.28‡ 150,633.48‡ 159,824.79‡ 168,793.50‡
Oncology without chemotherapy 30,894.37 54,351.70 72,104.95 89,200.67† 103,629.01* 114,179.69†
Adjusted CRPC-specific costs (US$)
Urology cohort (ref.) 10,666.83 16,259.84 20,028.80 22,226.95 23,692.21 25,081.09
Oncology with chemotherapy 26,042.74‡ 41,259.20‡ 53,476.65‡ 63,464.28‡ 66,685.71‡ 68,286.20‡
Oncology without chemotherapy 9,648.83 16,216.14 20,655.64 24,067.06 29,942.43 32,927.43
Notes: *P , 0.05; †P , 0.01; ‡P , 0.001.
Abbreviations: CRPC, castration-resistant prostate cancer; ref, reference group.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Patients appear to benefit from an integrated multidisciplinary 
approach and may receive more comprehensive health 
care if they seek treatment from more than one type of 
specialist.18,24,25
Incidence rates of medication use, including hormones 
and chemotherapy, were significantly higher among 
patients treated by oncologists than among those treated by 
urologists.
During the 6-month baseline and variable follow-up 
periods in our study, all treatments evaluated were used by 
significantly higher percentages of patients in the oncology 
cohort as compared to the urology cohort; the largest dif-
ferences between cohorts were seen for chemotherapy and 
radiation use. For patients in the oncology cohort, use of 
chemotherapy, radiation treatment, and other therapies 
increased considerably from the baseline to the variable-
length follow-up period. The oncology cohort had signifi-
cantly higher percentages of patients with use of docetaxel, 
inpatient stays, ER visits, and ambulatory visits compared to 
the urology cohort during the follow-up period. More than 
half of the patients in the oncology cohort and just under half 
of the urology cohort patients had inpatient stays during the 
follow-up period.
For both the oncology and urology cohorts, results of 
cost analyses indicate that the economic burden increases 
significantly as the disease progresses, both with regard to 
mean total health care costs and mean CRPC-specific total 
costs.
During the variable follow-up period, cost differences 
between the cohorts were significant for overall and CRPC-
specific total costs, medical costs, ambulatory costs, and 
pharmacy costs, as well as for CRPC-specific inpatient 
costs (but not for overall inpatient costs). After adjusting 
for other factors, adjusted total and CRPC-specific costs did 
not significantly differ between the cohorts when the use of 
chemotherapy among oncologists’ patients was factored into 
the analysis. During the first year of follow-up, total adjusted 
health care costs for the urology cohort were very similar to 
those seen for the oncology cohort without chemotherapy, but 
during years 1–6, adjusted total costs were much higher for 
the oncology cohort without chemotherapy than for patients 
in the urology cohort.
The costs observed in our study are in line with those 
reported in previous studies. A retrospective study of 3000 
prostate cancer patients receiving androgen deprivation ther-
apy reported a mean total cost of health care of US$48,350 
per patient over 36 months.38 In a study of 4553 patients 
with prostate cancer identified from a national registry, 
mean annual prostate cancer-related costs were US$7740 per 
patient, but the average cost per patient varied considerably 
by treatment type.39 And in a retrospective study of 2056 
patients with metastatic prostate cancer, average annual 
cost was US$30,626 per patient, as compared to an aver-
age annual cost of US$18,948 for those patients with PSA 
progression.40
In our study, the first year of adjusted total costs com-
prised 36% of the total costs at the end of the follow-up 
period for the oncology cohort and 27% of the total costs 
for the urology cohort. Evaluating only CRPC-specific costs, 
the first year of costs comprised 29% of the 6-year costs 
for the oncology without chemotherapy cohort, 38% of the 
6-year costs for the oncology with chemotherapy cohort, and 
43% of the final costs for the urology cohort. These percent-
ages are somewhat lower than those reported by Skolarus   
et al,33 who identified 105,961 patients diagnosed with pros-
tate cancer between 1992 and 2005 using SEER-Medicare 
data and found that, during the entire study period, the initial 
phase (ie, first year) of prostate cancer care comprised the 
greatest financial burden at US$987,774,979 (58% of total 
costs), followed by continuing care (32%) and end-of-life care 
(10%). However, the Skolarus et al33 estimates pertained to 
the initial phase of prostate cancer care, not the initial phase 
of CRPC care; patients with CRPC likely received treatment 
for their prostate cancer prior to their diagnosis of CRPC 
and those costs are not captured in the follow-up costs for 
the study population.
CRPC-specific mean total health care costs comprised 67% 
of overall mean total health care costs in the oncology cohort, 
and 42% in the urology cohort. These findings are in line with 
results reported by Fitzpatrick et al,18 who reported that aver-
age prostate cancer-related costs made up about 50% of the 
total all-cause health care costs incurred by their patients, and 
by Crawford et al,41 who found that prostate cancer-related 
costs represented 60% of the average total expenditures for 
the 2-year period after initial diagnosis. Krahn et al42 found a 
higher proportion of total costs to be attributable to prostate 
cancer in the first year after diagnosis (72%) but prostate 
cancer-specific costs comprised only 18%–35% of total costs 
in the other phases of their study.
This study was designed to examine differences in 
treatment patterns and differences in total and CRPC-specific 
health care costs and resource utilization between patients 
with CRPC treated by oncologists and those treated by 
urologists in a selected sample of 2585 patients. Our aim was Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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not to determine which patients fared better or to compare 
the quality of care delivered by these two types of specialists. 
Attempting to make such a comparison would not be feasible 
given the differences in patient characteristics between the 
two cohorts; namely, patients in the oncology cohort had 
greater comorbidity and were more likely to die during the 
follow-up period or to have other cancers during baseline as 
compared to patients in the urology cohort.
study limitations
Inherent limitations of retrospective claims analyses, as well 
as limitations specific to this study, should be considered 
when interpreting these results. There are limits to the degree 
to which claims data can accurately capture an individual’s 
medical history. Claims data are collected for the purpose of 
payment and not research, and are subject to possible coding 
errors, coding for the purpose of rule-out rather than actual 
disease, and undercoding. Furthermore, selection of study 
populations from claims data is a nonvalidated methodology. 
Nevertheless, administrative data allow for the examination 
of health care utilization and expenditure patterns in a real-
world setting, away from the highly controlled environment 
of clinical trials, and offer the advantage of large sample 
sizes with diverse medical histories. The presence of a 
prescription claim does not necessarily mean the drug was 
taken as prescribed, and patients who may have received 
drugs without the presence of a prescription claim (eg, by 
receiving samples from their physicians or obtaining medica-
tions outside of the health care pharmacy system) may not 
have been captured.
Limitations specific to this study must also be taken into 
account. The use of PSA levels as an indicator of CRPC, 
although supported by previous research, may have led to 
overidentification of patients with CRPC. Our results may 
also have been biased by our method of recording outcome 
measures on a PPPM basis to adjust for varying lengths 
of follow-up time. Another possible confounding factor is 
that patients who visited urologists and oncologists in the 
same office could not be discerned from the claims data. 
Furthermore, not all patients in the oncology cohort were 
treated exclusively by oncologists; most (83%) were also 
treated by urologists. By definition, none of the patients 
in the urology cohort also visited an oncologist. Thus, it 
is difficult to determine whether differences in health care 
resource utilization and cost outcomes are due to a difference 
in treatment patterns between the two types of specialists 
or to other factors such as age, comorbidity, and severity of 
disease. As a sensitivity analysis, we examined the treatment 
patterns stratifying the oncologist cohort by whether the 
patients had also visited an urologist. Our results (tables not 
shown) indicated that there was a statistically significant dif-
ference in the number of comorbid conditions, with patients 
in the oncology-only group having an average of one fewer 
condition than the oncology + urology group (P , 0.001). 
However, there were no statistically significant differences 
between the groups with regard to demographics; Charlson 
comorbidity score; incidence rate of use of hormone, che-
motherapy, radiation, or other therapy, or in use of specific 
types of chemotherapy.43
This study might have been enhanced by an examination 
of the costs of any previous or ongoing surgical interventions 
incurred by the two patient cohorts. However, data obtained 
for this study were limited to a 6-month pre-index period. 
The study patients may in fact have been undergoing treat-
ment for several years.
It should also be noted that results may not be gen-
eralizable to the entire US prostate cancer population, 
such as younger patients, those with fewer comorbidi-
ties, or those with less advanced disease. And since both 
commercially insured and Medicare Advantage plan 
members were included in this study, differences in the 
way services are covered may have resulted in different 
utilization patterns among these two types of enrollees. 
However, the plans used for analysis encompass a wide 
US geographic distribution and therefore provide the 
capability for generalization to managed care populations 
on a national level.
Conclusion
This study adds to the scant literature examining costs asso-
ciated with treating advanced-stage prostate cancer. A few 
studies have been conducted in clinical settings, but for the 
most part they have evaluated patients receiving a specific 
treatment. A clearer understanding of treatment patterns and 
costs associated with advanced-stage prostate cancer may 
help to inform treatment decisions or identify areas where 
new treatment options could reduce the economic burden on 
the health care system. Future studies evaluating the differ-
ences in practice patterns between urologists and oncologists 
that also assess the implications of these differing patterns 
in terms of outcomes would represent an important addition 
to the literature.
In this study, patients who were treated by oncologists, 
particularly those using chemotherapy, had higher total and 
prostate cancer-related health care costs than CRPC patients 
treated by urologists. In addition, CRPC patients treated by Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
243
Differences in CRPC treatment patterns
oncologists had greater use of hormones, chemotherapy, 
and radiation, and higher percentages of patients with 
inpatient stays, ER, and ambulatory visits, as compared to 
patients treated by urologists. However, oncologist-treated 
patients who were not using chemotherapy had treatment 
patterns and costs that were very similar to those observed 
in the urologist-treated cohort, suggesting that differences in 
costs between the two cohorts may be driven primarily by 
differences in severity of illness.
Our study appears to be the most extensive analysis of 
comparisons of treatment patterns, health care resource uti-
lization, and costs between patients treated by oncologists 
and those treated by urologists. Previous research compar-
ing prostate cancer treatment approaches of urologists to 
those of oncologists has primarily focused on patients with 
early-stage disease whereas we have evaluated comparative 
treatment approaches between these two types of specialists 
for late-stage disease.
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Appendix Chemotherapy agents included in medication subclasses
Subclass Medication
Alkylating agents Bendamustine
Busulfan
Carmustine
Carmustine/polifeprosan
Chlorambucil
Cyclophosphamide
Dacarbazine
Estramustine
ifosfamide
Lomustine
Mechlorethamine
Melphalan
Procarbazine
streptozocin
Temozolomide
Thiotepa
Uracil mustard
Carboplatin
Cisplatin
Oxaliplatin
Antimetabolites Methotrexate
Pemetrexed
Cladribine
Clofarabine
Cytarabine
Fludarabine
Mercaptopurine
Nelarabine
Pentostatin
Thioguanine
Azacitidine
Capecitabine
Floxuridine
Fluorouracil
gemcitabine
hydroxyurea
Docetaxel (taxotere) Docetaxel
Other antimicrotubule agents Paclitaxel
Albumin-bound paclitaxel
Vinblastine
Vincristine
Vinorelbine
ixabepilone
Topoisomerase-active agents irinotecan
Topotecan
Daunorubicin
Doxorubicin
(Continued)
Appendix (Continued)
Subclass Medication
Pegylated liposomal
Doxorubicin
Epirubicin
idarubicin
Mitoxantrone
Valrubicin
Etoposide
  Teniposide
Antineoplastic antibiotics Bleomycin
Dactinomycin
Mitomycin C
Plicamycin
Biologically directed therapies Alitretinoin
Bexarotene
Bortezomib
Dasatinib
Erlotinib
Gefitinib
imatinib
Lapatinib
Nilotinib
sorafenib
sunitinib
Temsirolimus
Tretinoin
Alemtuzumab
Bevacizumab
Cetuximab
gemtuzumab
ibritumomab
Panitumumab
Rituximab
Tositumomab
Trastuzumab
Immune therapies Aldesleukin (iL-2)
interferon alfa-2a
interferon alfa-2b
Lenalidomide
Thalidomide
Miscellaneous agents Altretamine
Arsenic trioxide
Asparaginase
Bcg vaccine
Decitabine
Denileukin
Levamisole
Mitotane
Pegaspargase
Porfimer
strontium-89
Vorinostat
Zoledronic acid (zometa) Zoledronic acid
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